Periodic Reporting for period 1 - OVACell (Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer)

ErVimmune develops breakthrough immunotherapies combining cancer vaccines and T cell-based therapies. The major step is the choice of a target specifically expressed by cancer cells and shared between patients. Human endogenous retroviruses (HERVs) answered to these two...